Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 - Orexigen Therapeutics, Inc. | orex-ex321_11.htm |
| EX-31.2 - EX-31.2 - Orexigen Therapeutics, Inc. | orex-ex312_8.htm |
| EX-31.1 - EX-31.1 - Orexigen Therapeutics, Inc. | orex-ex311_9.htm |
| 10-K - 10-K - Orexigen Therapeutics, Inc. | orex-10k_20161231.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the following Registration Statements:
(1) Registration Statements (Form S-3 Nos. 333-207961 and 333-210224) of Orexigen Therapeutics, Inc. and
(2) Registration Statements (Form S-8 Nos. 333-142405, 333-165442, 333-175071, 333-189120, 333-194951, 333-202763, and 333-214771) pertaining to the Orexigen Therapeutics, Inc. Amended and Restated 2007 Equity Incentive Award Plan, 2004 Stock Plan and the Orexigen Therapeutics, Inc. 2013 Employee Stock Purchase Plan;
of our report dated March 29, 2017, with respect to the consolidated financial statements of Orexigen Therapeutics, Inc. included in this Annual Report (Form 10-K) of Orexigen Therapeutics, Inc. for the year ended December 31, 2016.
|
|
/S/ Ernst & Young LLP |
|
|
|
|
San Diego, California |
|
|
March 29, 2017 |
|